Top Suppliers:I want be here

84680-54-6

84680-54-6 structure
84680-54-6 structure
  • Name: Enalaprilat Dihydrate
  • Chemical Name: enalaprilat dihydrate
  • CAS Number: 84680-54-6
  • Molecular Formula: C18H28N2O7
  • Molecular Weight: 384.424
  • Catalog: Biochemical Inhibitor Endocrinology & Hormones RAAS inhibitor
  • Create Date: 2018-10-17 13:29:56
  • Modify Date: 2024-01-05 22:10:20
  • Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.Target: ACEEnalaprilat has high affinity for human endothelial ACE with IC50 of 1.94 nM in vitro binding assay by displacing a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments [1]. Enalaprilat attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with IC50 of 90 mM [2].Administration of Enalaprilat induces a significant reduction of MAP at 70 minutes compared with the placebo group during haemorrhagic shock in rats, and results in a 50% reduction of CO, a general tendency of EB extravasation which is significant in the kidney and lungs, and a significant increase in ileal EB extravasation (53%) [3].

Name enalaprilat dihydrate
Synonyms MFCD00941393
ENALAPRILAT DIHYDRATE
2-[N-(1-Carboxy-3-phenylpropyl)alanyl]-1-pyrrolidinecarboxylic acid dihydrate
EINECS 278-459-3
1-Pyrrolidinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-, hydrate (1:2)
Description Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.Target: ACEEnalaprilat has high affinity for human endothelial ACE with IC50 of 1.94 nM in vitro binding assay by displacing a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments [1]. Enalaprilat attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with IC50 of 90 mM [2].Administration of Enalaprilat induces a significant reduction of MAP at 70 minutes compared with the placebo group during haemorrhagic shock in rats, and results in a 50% reduction of CO, a general tendency of EB extravasation which is significant in the kidney and lungs, and a significant increase in ileal EB extravasation (53%) [3].
Related Catalog
References

[1]. Ceconi, C., et al., Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol, 2007. 577(1-3): p. 1-6.

[2]. van Eickels, M., H. Vetter, and C. Grohe, Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation. Br J Pharmacol, 2000. 131(8): p. 1592-6.

[3]. Schumacher, J., et al., Effects of candesartan and enalaprilat on the organ-specific microvascular permeability during haemorrhagic shock in rats. Br J Anaesth, 2006. 96(4): p. 437-43.

Boiling Point 563.5ºC at 760 mmHg
Melting Point 211-215°C
Molecular Formula C18H28N2O7
Molecular Weight 384.424
Flash Point 294.6ºC
Exact Mass 384.189636
PSA 125.40000
LogP 1.32630
Index of Refraction 1.579
Storage condition -20°C Freezer
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xi
Risk Phrases R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases S22-S26-S36/37/39
RIDADR NONH for all modes of transport
RTECS TW3590600